You are here

  • Home
  • Archive
  • Volume 16, Issue 6
  • In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding

https://doi.org/10.1136/ebm.2011.0023

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests RDL and DAG are members of the ARISTOTLE trial's Steering Committee.